Navigation Links
Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
Date:9/21/2009

possibility that brought me to Merrimack and makes MM-121 and MM-111 such promising oncology therapeutic candidates."

Prior to GSK, Dr. Niyikiza held the position of Lilly Research Fellow and Global Oncology Pharmacogenomics Leader at Eli Lilly. He has also worked with Syntex Research and as a Visiting Professor of Mathematics with Indiana University. Dr. Niyikiza received his Doctorate and Masters degrees from Indiana University and a Masters from the African Institute of Statistics and Applied Economics in Kigali, Rwanda.

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in clinical development. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well-tolerated therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts.


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
4. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
5. Sunesis Pharmaceuticals Receives NASDAQ Notification
6. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
8. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
9. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
10. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
11. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in automated ... for hospitals, will be exhibiting at booth #209 at ... & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... hospitals cleaner, reducing infection risk and saving millions in ... Staff will be available at booth #209 to ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... TUSTIN, Calif., Sept. 1 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 ... New York Palace Hotel in New York City. , , ... the Investors section of Peregrine,s website at www.peregrineinc.com . ...
... COPENHAGEN and OSLO, September ... medicines company, today announced that it,has appointed two ... Robert Burns, previously CEO of Celldex Therapeutics Inc., ... new Chief Executive,Officer. Dr Alexander Duncan, previously SVP ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that its Senior ... will present a corporate overview at the upcoming Rodman ... September 9, 2009 at 12:30 p.m. (eastern time) in ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/29/2014)... If you,ve ever ordered the wrong food at a restaurant, ... may have less to do with what you want and ... After analyzing 217 menus and the selections of over 300 ... International Journal of Hospitality Management showed that when it ... most: what you see on the menu and how you ...
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... in their response to sleep deprivation, but the biological ... Researchers have now found that a genetic difference in ... sensitive to the effects of sleep deprivation. The findings, ... the University of Surrey's Sleep Research Center, appear online ...
... upon a massive database established with funds from the ... of the National Institutes of Health (NIH), scientists have ... influenza A virus epitopes--the critical sites on the virus ... reported by researchers at the La Jolla Institute for ...
... first draft of the horse genome sequence has been ... use by biomedical and veterinary researchers around the globe, ... today. , The $15 million effort to sequence the ... of the horse (Equus caballus) was funded by the ...
Cached Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2New details on how the immune system recognizes influenza 2New details on how the immune system recognizes influenza 3New details on how the immune system recognizes influenza 4Horse genome assembled 2Horse genome assembled 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: